Pulmonary Disease, Chronic Obstructive  >>  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT02345161: A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
3
1811
Europe, RoW
Triple FF/UMEC/VI, Placebo to match FF/UMEC/VI, Budesonide/Formoterol, Placebo to match Budesonide/Formoterol combination, Albuterol/salbutamol
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
04/16
04/16
IMPACT, NCT02164513: A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
3
10355
Europe, Canada, Japan, US, RoW
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
07/17
07/17

Download Options